Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia

PURPOSE: Colony-stimulating factor-3 receptor (CSF3R)-T618I is a recurrent activating mutation in chronic neutrophilic leukemia (CNL) and to a lesser extent in atypical chronic myeloid leukemia (aCML) resulting in constitutive JAK-STAT signaling. We sought to evaluate safety and efficacy of the JAK1...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Oncol
Egile Nagusiak: Dao, Kim-Hien T., Gotlib, Jason, Deininger, Michael M.N., Oh, Stephen T., Cortes, Jorge E., Collins, Robert H., Winton, Elliot F., Parker, Dana R., Lee, Hyunjung, Reister, Anna, Schultz, Savage, Samantha, Stevens, Brockett, Chase, Subbiah, Nan, Press, Richard D., Raess, Philipp W., Cascio, Michael, Dunlap, Jennifer, Chen, Yiyi, Degnin, Catherine, Maxson, Julia E., Tognon, Cristina E., Macey, Tara, Druker, Brian J., Tyner, Jeffrey W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Clinical Oncology 2020
Gaiak:
RAPID COMMUNICATIONS
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106977/
https://ncbi.nlm.nih.gov/pubmed/31880950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00895
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak